These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32961235)

  • 1. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
    Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
    Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
    Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
    Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
    Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
    J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.
    Moreira GV; Azevedo FF; Ribeiro LM; Santos A; Guadagnini D; Gama P; Liberti EA; Saad M; Carvalho C
    J Nutr Biochem; 2018 Dec; 62():143-154. PubMed ID: 30292107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition.
    Chen J; Ding X; Wu R; Tong B; Zhao L; Lv H; Meng X; Liu Y; Ren B; Li J; Jian T; Li W
    J Agric Food Chem; 2021 Dec; 69(47):14176-14191. PubMed ID: 34783554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
    Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
    Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
    He Q; Sha S; Sun L; Zhang J; Dong M
    Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tangerine Peel-Derived Exosome-Like Nanovesicles Alleviate Hepatic Steatosis Induced by Type 2 Diabetes: Evidenced by Regulating Lipid Metabolism and Intestinal Microflora.
    Zou J; Song Q; Shaw PC; Wu Y; Zuo Z; Yu R
    Int J Nanomedicine; 2024; 19():10023-10043. PubMed ID: 39371479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
    J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
    Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
    Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet.
    Zhang N; Tao J; Gao L; Bi Y; Li P; Wang H; Zhu D; Feng W
    Biomed Res Int; 2020; 2020():2947549. PubMed ID: 32149099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].
    Zou JJ; Li H; Zhou M; Huang QQ; Wu YJ; Yu R
    Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(2):525-533. PubMed ID: 36725242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.